IRHYTHM TECHNOLOGIES INC

NASDAQ: IRTC (iRhythm Holdings, Inc.)

Last update: 27 Feb, 3:58PM

133.40

-6.78 (-4.84%)

Previous Close 140.18
Open 137.74
Volume 556,420
Avg. Volume (3M) 601,229
Market Cap 4,298,033,664
Price / Sales 4.98
Price / Book 24.60
52 Weeks Range
92.52 (-30%) — 212.00 (58%)
Earnings Date 30 Apr 2026
Profit Margin -15.90%
Operating Margin (TTM) -19.49%
Diluted EPS (TTM) -3.12
Quarterly Revenue Growth (YOY) 20.30%
Total Debt/Equity (MRQ) 848.67%
Current Ratio (MRQ) 5.71
Operating Cash Flow (TTM) 47.53 M
Levered Free Cash Flow (TTM) 26.95 M
Return on Assets (TTM) -4.37%
Return on Equity (TTM) -111.13%

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Bearish
Medical Devices (Global) Mixed Bearish
Stock iRhythm Holdings, Inc. Bearish Bullish

AIStockmoo Score

-0.7
Analyst Consensus 1.0
Insider Activity -3.0
Price Volatility 1.0
Technical Moving Averages 1.5
Technical Oscillators -4.0
Average -0.70

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
IRTC 4 B - - 24.60
TMDX 4 B - 23.39 10.16
ESTA 2 B - - 78.01
UFPT 2 B - 24.49 3.47
PRCT 2 B - - 3.97
IRMD 1 B 1.19% 58.16 13.41

iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Sector Healthcare
Industry Medical Devices
Investment Style Small Growth
% Held by Insiders 1.08%
% Held by Institutions 115.08%
52 Weeks Range
92.52 (-30%) — 212.00 (58%)
Price Target Range
198.00 (48%) — 244.00 (82%)
High 244.00 (Needham, 82.91%) Buy
Median 205.00 (53.67%)
Low 198.00 (Canaccord Genuity, 48.43%) Buy
Average 210.13 (57.52%)
Total 8 Buy
Avg. Price @ Call 152.26
Firm Date Target Price Call Price @ Call
Citigroup 11 Mar 2026 214.00 (60.42%) Buy 119.64
Truist Securities 23 Feb 2026 200.00 (49.93%) Buy 141.22
Baird 20 Feb 2026 200.00 (49.93%) Buy 150.96
Canaccord Genuity 20 Feb 2026 198.00 (48.43%) Buy 150.96
JP Morgan 20 Feb 2026 215.00 (61.17%) Buy 150.96
Wells Fargo 20 Feb 2026 200.00 (49.93%) Buy 150.96
13 Jan 2026 225.00 (68.67%) Buy 155.44
Needham 12 Jan 2026 244.00 (82.91%) Buy 168.99
Evercore ISI Group 05 Jan 2026 210.00 (57.42%) Buy 184.39
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
SMITH MERVIN - 113.77 -2,585 -294,095
Aggregate Net Quantity -2,585
Aggregate Net Value ($) -294,095
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 113.77
Name Holder Date Type Quantity Price Value ($)
SMITH MERVIN Officer 16 Mar 2026 Automatic sell (-) 2,585 113.77 294,095

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria